Tirzepatide targets two receptors, GLP-1 and GIP, and pushes weight loss to about 20-22%
These findings indicate that clinicians can now recognise semaglutide as a vascular protective medication, with benefits that extend beyond lowering weight or A1C, said Subodh Verma (University of Toronto, Toronto, Canada), senior author of the STRIDE trial
With our GLP-1 therapy treatment options for San Diego residents, every step is guided by a doctor who listens, explains, and tailors care to your needs: no generic programs, no shortcuts just thoughtful treatment designed to work for you
GLP-1 medications are administered subcutaneously (under the skin) into areas with adequate subcutaneous fattypically the abdomen, thigh, or upper arm
FOR PEOPLE WHO ARE OBESE OR OVERWEIGHT TEND TO BE GOOD CANDIDATES SOURCE: National Institute of Diabetes and Digestive and Kidney Diseases